Pliant Therapeutics Inc.

07/15/2024 | Press release | Distributed by Public on 07/15/2024 12:58

Pliant Therapeutics Announces Positive Long Term Data from the INTEGRIS PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.